Your browser doesn't support javascript.
loading
Biomarkers for development of cancer vaccines.
Whelan, Mike; Ball, Graham; Beattie, Chris; Dalgleish, Angus.
Afiliação
  • Whelan M; St George's Hospital Medical School, Onyvax Ltd, Cranmer Terrace, London, SW17 0RE, UK. mwhelan@onyvax.com.
  • Ball G; Nottingham Trent University, School of Biomedical and Natural Sciences, Clifton Campus, Clifton Lane, Nottingham, NG11 8NS, UK.
  • Beattie C; St George's Hospital Medical School, Onyvax Ltd, Cranmer Terrace, London, SW17 0RE, UK.
  • Dalgleish A; St George's Hospital Medical School, Department of Oncology, Cranmer Terrace, London, SW17 0RE, UK. dalgleis@sgul.ac.uk.
Per Med ; 3(1): 79-88, 2006 Feb.
Article em En | MEDLINE | ID: mdl-29783432
ABSTRACT
The search for molecules that correlate with cancer progression is an evolving and exciting area of research. Such biomarkers have utility in a number of areas, most notably in a variety of clinical development programs. Modern technologies are revealing multiple potential biomarker candidates. However, the challenge remains in validating the correlation in levels of a particular molecule with clinical parameters. In this article, the area of biomarkers and cancer vaccines is briefly reviewed and the possibility of combining multiple molecules to generate a profile that correlates with outcome, rather than using more conventional single molecule biomarker systems, is explored.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2006 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2006 Tipo de documento: Article